The company will forgo $180 million due to the contract’s termination, executives told investors on a call.
Emergent Biosolutions shares plunge more than 38% after U.S. cancels deal with Covid vaccine maker
Share This Story, Choose Your Platform!
About the Author: David Hilbern
